GLP-1 supply has been the single most volatile supply-chain question in UK pharma since 2023. Wegovy (semaglutide) and Mounjaro (tirzepatide) have alternated between abundance and constraint depending on manufacturer capacity, MHRA decisions, and shifts in DHSC guidance. This piece is a structural map of where UK GLP-1 supply actually comes from, what bottlenecks recur, and what the 2026 to 2027 outlook looks like.
Where UK GLP-1 supply comes from — manufacturers, importers, MHRA approvals
Wegovy (semaglutide) is manufactured by Novo Nordisk. Mounjaro (tirzepatide) is manufactured by Eli Lilly. Both are licensed products in the UK with MHRA approval; both are subject to manufacturer-controlled allocation. UK supply is wholesaled through licensed importers and distributed to GPhC-registered pharmacies for prescription dispensing.
The 2023 to 2025 supply situation — what was constrained and when
DHSC has issued multiple medicine supply notifications relating to GLP-1 medications since 2023. The pattern was: tight supply during peak demand quarters, intermittent stock-outs at individual dose strengths (particularly higher-dose Wegovy pens), and shifting MHRA Drug Safety Updates on prescribing scope. Brands that built their patient pipelines on the assumption of unlimited stock were hit hardest.
Compounded specials as a supply alternative
MHRA Specials regulations allow compounded preparations where no licensed alternative meets the patient's need. Compounded semaglutide and tirzepatide are dispensed under this framework with full UK pharmacy oversight. The legal basis is narrow — Specials is not a workaround for supply shortages of commercial products. Prescriber discretion applies on every individual case.
DHSC and MHRA communications on GLP-1 supply
DHSC publishes medicine supply notifications which UK pharmacies and prescribers are expected to follow. MHRA issues Drug Safety Updates with prescribing-relevant changes. Brands operating in weight management need to monitor both in real time — a DHSC supply update on a Friday can change Monday's patient experience.
Outlook for 2026 to 2027 — pipeline of new GLP-1 entrants
The competitive pipeline for GLP-1 receptor agonists is significant. Multiple new molecules and combination products are in late-stage development. Generic semaglutide is on a longer horizon. The medium-term outlook is more supply, more dose options, and gradually decreasing per-patient costs. Short-term volatility remains likely.
What clinics and brands should plan for
Three practical planning steps. Run scenario modelling for a 30-day supply disruption on your highest-volume SKU. Have a clear patient-communication template for supply-driven dose substitutions. Diversify your dispensing partner if your business depends on a single channel for compounded specials. Volatility is not exceptional — it is the operating environment.
GLP-1 supply will remain a planning variable for at least another 24 months. Operators who model for volatility — rather than hoping it ends — build more resilient businesses.
DHSC supply updates on a Friday change Monday's patient experience. Plan accordingly.
GLP-1 is the most strategically important category for many UK telehealth brands right now. Treating supply as a first-class operational concern — rather than something the dispensing partner handles — is what separates resilient businesses from fragile ones.
